Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 22-30

  Hartmann, Gunther ^b   Bidlingmaier, Christoph ^b   Siegmund, Britta ^b   Albrich, Stefan ^b   Schulze, Johannes ^b   Tschoep, Katharina ^b   Eigler, Andreas ^b   Lehr, Hans Anton ^b   Endres, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; PHOSPHOLIPASE; PHOSPHOLIPASE INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; COLITIS; DEXTRAN SULFATE; FECES; FEMALE; HEMORRHAGE; MICE; MICE, INBRED BALB C; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033957727     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA and Torphy TJ (1996) Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem Pharmacol 51:949-956.
2. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A and Schreiber S (1997) Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40:470-494.
3. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748.
4. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA and MacDonald TT (1994) Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106:1455-1466.
5. Cooper HS, Murthy SN, Shah RS and Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-249.
6. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP and Elson CO (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643-1652.
7. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G and Endres S (1998) Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukocyte Biol 63:101-107.
8. Eigler A, Sinha B, Hartmann G and Endres S (1997) Taming TNF: Strategies to restrain this proinflammatory cytokine. Immunol Today 18:487-492.
9. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H and Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
10. Elson CO, Sartor RB, Tennyson GS and Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367.
11. Essayan DM, Huang SK, Undem BJ, Kagey-Sobotka A and Lichtenstein LM (1994) Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153:3408-3416.
12. Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE and Warrell DA (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 335:311-315.
13. Fischer W, Schudt C and Wendel A (1993) Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem Pharmacol 45:2399-2404.
14. Gantner F, Kusters S, Wendel A, Hatzelmann A, Schudt C and Tiegs G (1997) Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J Pharmacol Exp Ther 280:53-60.
15. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J and Hauser SL (1995) Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 92:3601-3605.
16. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensens S and Torphy TJ (1998) SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor-α and interleukin-4 production in vivo. J Pharmacol Exp Ther 287:705-711.
17. Kim HS and Berstad A (1992) Experimental colitis in animal models. Scand J Gastroenterol 27:529-537.
18. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V and Falk W (1997) Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107:353-358.
19. Lehr HA, Mankoff DA, Corwin D, Santeusanio G and Gown AM (1997) Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45:1559-1565.
20. Murch SH, Braegger CP, Walker-Smith JA and MacDonald TT (1993) Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709.
21. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA and MacDonald TT (1991) Serum concentrations of tumour necrosis factor-α in childhood chronic inflammatory bowel disease. Gut 32:913-917.
22. Nyman U, Mussener A, Larsson E, Lorentzen J and Klareskog L (1997) Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol 108:415-419.
23. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702.
24. Olson AD, DelBuono EA, Bitar KN and Remick DG (1995) Antiserum to tumor necrosis factor and failure to prevent murine colitis. J Pediatr Gastroenterol Nutr 21:410-418.
25. Peterson TC and Davey K (1997) Effect of acute pentoxifylline treatment in an experimental model of colitis. Aliment Pharmacol Ther 11:575-580.
26. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ. Smith EFr, Lee JC and Esser KM (1994) Characterization of cAMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 16:805-816.
27. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hozegand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF and Van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405.
28. Reimund JM, Duraont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P and Duclos B (1997) In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40:475-480.
29. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN and Feldmann M (1997) Suppression of TNF-α expression, inhibition of Th1 Activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159:6253-6259.
30. Sandborn WJ and Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 5:119-133.
31. Savendahl L, Underwood LE, Haldeman KM, Ulshen MH and Lund PK (1997) Fasting prevents experimental murine colitis produced by dextran sulfate sodium and decreases interleukin-1β and insulin-like growth factor 1 messenger ribonucleic acid. Endocrinology 138:734-740.
32. Schade FU and Schudt C (1993) The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 230:9-14.
33. Seldon PM, Barnes PJ, Meja K and Giembycz MA (1995) Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol Pharmacol 48:747-457.
34. Semmler J, Wachtel H and Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15:409-413.
35. Siegmund B, Eigler A, Moeller J, Greten TF, Hartmann G and Endres S (1997) Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents. Eur J Pharmacol 321:231-239.
36. Sinha B, Semmler J, Eisenhut T, Eigler A and Endres S (1995) Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 25:147-153.
37. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J and Martin R (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1:244-248.
38. Souness JE, Houghton C, Sardar N and Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750.
39. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA and Hawkey CJ (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349:521-524.
40. Stricter RM, Remick DG, Ward PA, Spengler RN, Lynch JPd, Larrick J and Kunkel SL (1988) Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 155:1230-1236.
41. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF and Rutgeerts PJ (1997) A short-term study of chimenc monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035.
42. Turner CR, Andresen CJ, Smith WB and Watson JW (1994) Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 149:1153-1159.
43. van Deventer SJ (1997) Tumour necrosis factor and Crohn's disease. Gut 40:443-448.
44. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN and Woody J (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135.
45. Wachtel H (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22:267-272.